Given the lack of prognostic markers and cancer-antigen targets in lung adenocarcinoma (ADC), we sought to determine whether mesothelin, a cell-surface cancer-associated antigen expressed in lung ADC, could influence patient outcomes and tumor phenotype. Mesothelin was expressed in 69% of early-stage lung ADC, with strong expression in one of five patients. Highlevel expression of mesothelin was associated with reduced overall and recurrence-free survival in a multivariate analysis. In orthotopic and metastatic mouse models of lung ADC, human and murine lung ADC cells overexpressing mesothelin demonstrated increased in vivo proliferation and tumor progression and decreased survival. In summary, mesothelin is a potential biomarker and a candidate for targeted therapy in lung ADC.
Introduction
For patients with lung adenocarcinoma (ADC), the most frequent subtype of lung cancer (1) , prognosis is stage dependent: 5-year survival is 73% for stage IA patients, 58% for stage IB patients, and 24% for stage IIIA patients, even after combined chemotherapy and resection with curative intent (2) . Currently, targeted therapy is available for EGFR mutant tumors, which constitute 15% of lung ADC tumors (3) (4) (5) . For patients with EGFR wild-type tumors, no clinical or molecular biomarker (other than stage) has been prospectively demonstrated to further inform decision-making. While molecular-targeted approaches such as targeted cellular immunotherapy are promising (6) , candidate target antigens in lung ADC are limited and require further investigation.
Mesothelin (MSLN) is a cell-surface glycoprotein overexpressed in mesothelioma and
pancreatic and ovarian carcinomas (7) and is associated with poor prognoses (8, 9) . Furthermore, MSLN has been shown to promote peritoneal metastasis in ovarian ADC via its binding interaction with CA-125 (10) and its suppression of cell death (11) . MSLN expression is associated with neoplastic progression in Barrett's-associated esophageal ADC (12) and in triplenegative breast cancer (13) . Although the expression of MSLN in lung ADC has been previously described in a small cohort of patients (14) , its clinical and biological significance remain undefined. To further delineate the role of MSLN in lung ADC, we examined its expression, clinical characteristics, and patient survival in the largest series to date. On the basis of our clinical observations, we hypothesized that MSLN expression in lung ADC promotes an aggressive tumor phenotype, resulting in poor outcomes.
Research. Author Manuscript Published OnlineFirst on December 13, 2013; DOI: 10.1158/1078-0432.CCR- (1%-50%), or 2 (51%-100%). The sum of the MSLN stain intensity and the distribution grade determined the total MSLN score, ranging from 0 to 5. The MSLN score for each patient was then determined using the average of all of the patient's tumor cores (16) .
Mutation and gene expression analysis
After histologic confirmation of lung ADC, DNA was extracted from tumor specimens.
EGFR exon 19 deletions and exon 21 L858R mutations were identified by polymerase chain reaction, as described previously (17) . Standard direct sequencing was used to identify KRAS codon 12 and 13 mutations (18) .
In vitro assays
Human lung ADC cell lines H1299 and A549 and Lewis lung carcinoma (LLC) mouse lung ADC cells were purchased from the American Type Culture Collection, grown in standard media, and used for cell flow cytometric analyses, cell proliferation assays (using a Countess automated cell counter; Invitrogen, Carlsbad, CA), and invasion/migration Boyden chamber assays (using BD Matrigel Chambers; BD Biosciences, San Jose, CA). Green fluorescent protein (GFP)-firefly luciferase fusion and human MSLN genes were transduced into lung ADC cells by use of SFG retroviral vectors, as described previously (15) 
Statistical analysis
Associations between clinicopathologic variables and TMA findings were analyzed using Author Manuscript Published OnlineFirst on December 13, 2013; DOI: 10.1158/1078-0432.CCR- score was identified in the training set by use of the minimum P value approach (20) and confirmed in the validation set. Once the cutoff was determined in this manner, the remaining results were reported for the entire cohort. RFS and OS were estimated using the Kaplan-Meier method. A Cox proportional hazards model was used to evaluate the independent association between MSLN expression and OS. The model was stratified by stage, to account for subpopulation differences, and adjustment was made for clinicopathologic variables that were correlated with OS in univariate analysis. All P values were based on two-tailed statistical analysis, and P<0.05 was considered to indicate statistical significance. All clinical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). Preclinical data were analyzed with GraphPad Prism (La Jolla, CA).
Results

Lung ADC MSLN expression and RFS and OS
Of the 1209 patients who underwent anatomic resection and had an adequate specimen available for immunohistochemical analysis (Table 1) , 69% had detectable levels of MSLN in their tumor, with no MSLN staining detected in normal lung tissue or tumor stroma. Specifically, we observed that individual tumor cells demonstrate strong cytoplasmic staining and mixed membranous staining with varying intensity and distribution ( Supplementary Fig. S1A&B ). This pattern of mesothelin staining is similar to what has been previously described (21) . The distribution of MSLN scores among all patients is presented in Figure 1A to 1B.
The systematic search for an optimal cutoff point in the training set indicated that the best separation, with respect to OS, was provided by categorizing low MSLN (score, 0-4) versus high MSLN (score, 5) (χ Among patients with stage I disease (n=987), five-year OS was 72% (95% CI, 67%-75%) for patients with low-level MSLN expression and 60% (95% CI, 43%-72%) for patients with high-level expression (P=0.003; Fig. 2C ). RFS was similarly improved in patients with stage I lung ADC with low MSLN (P=0.005; Fig. 2D ). In the multivariate analysis ( 
Lung ADC MSLN expression and clinicopathologic characteristics
We noted no morphologic differences between cultured cells overexpressing MSLN and (Fig. 3) .
MSLN expression promotes increased tumor progression and decreased survival in mouse models of lung ADC
Mice with MSLN(+) H1299M tumors accumulated a greater BLI signal over time, suggesting an increased rate of tumor progression in vivo (Fig. 4A-B dominant tumor cell population over time (Fig. 4D) . This result was significant at days 24 (66% vs 29%; P<0.01) and 31 (87% vs 12%; P<0.001).
We sought to confirm these findings in an immunocompetent syngeneic model of metastatic lung ADC. LLC cells stably transduced to overexpress murine MSLN were designated "LLCmM." We observed an increase in cell invasion in vitro with MSLN overexpression (Supplementary Fig. S2 ) as well as demonstrated a decreased survival (38 vs 29 days; P =.0012; Supplementary Fig. S2 ) in mice with intravenously induced LLCmM tumors.
Discussion
In this study, we observed that MSLN is commonly expressed in lung ADC, even in stage I patients. In the largest series to date of patients with stage I to III lung ADC, MSLN expression correlated with decreased RFS and OS. In the multivariate analysis, high-level MSLN expression remained an independent predictor of survival. With these clinical observations, we hypothesized that MSLN expression was an independent driver of an aggressive tumor phenotype. The impetus to explore the expression and biological influence of MSLN on lung ADC is driven by (a) the lack of a clinically applicable molecular biomarker for the majority of lung ADC cases (other than EGFR mutation status), (b) the lack of targeted therapy for the majority of patients with lung ADC, (c) the evidence that MSLN-specific immune responses prolong survival in patients with pancreatic cancer, and (d) the promising preclinical and ongoing early-phase clinical studies that have demonstrated that MSLN may be an effective cancer antigen to target with immunotherapy in solid tumors (22) (23) (24) .
In our study cohort, high-level MSLN expression was associated with male sex, history of smoking, and papillary-predominant lung ADC histologic subtype. More importantly, our data Supplementary Fig. S3 ). Furthermore, MSLN expression remains present in lung ADC from stage I to stage III. Perhaps most importantly, targeting MSLN-expressing lung ADC, which is resistant to the current standard-of-care therapy, provides a new therapeutic opportunity. Targeting MSLN with the immunotoxin SS1P has shown in vivo specificity and antitumor activity (26) (27) (28) , including in patients with non-small cell lung cancer (29) .
The immunogenicity of MSLN as a viable cellular therapy target has been demonstrated in vaccine trials using pancreatic ADC cells and granulocyte-macrophage colony-stimulating factor. MSLN-targeted adoptive T-cell therapies have demonstrated efficacy in preclinical models of mesothelioma and ovarian cancer (23, 30) , and this approach is currently being tested in clinical trials for other malignancies (6).
MSLN is a molecular marker commonly expressed in lung ADC, and as an independent predictor of worse survival, it identifies a tumor phenotype with increased aggressiveness and 
